In the world of health care innovation, speed matters. But when it comes to developing and deploying cutting-edge treatments and therapeutics safely, a cautious and methodical approach is vital as well. Safety matters as much as speed, but faster doesn’t always mean riskier. In her latest blog, AMCP CEO Susan Cantrell discusses the history of the Pre-approval Information Exchange (PIE) Act and how it will help patients.
In this guest blog post, Jennifer Graff, PharmD , discusses incorporating value in coverage decisions and how this applies to AMCP's efforts in addressing value and access.
In 2016, AMCP made pre-approval information exchange (PIE) a legislative priority recognizing its vital importance to patients. On June 8, 2022, the U.S. House of Representatives passed the PIE Act of 2022. Learn more about PIE as a legislative priority for AMCP.
The aim of the AMCP Format is to identify comprehensive evidence and information elements that meet the evidentiary needs of HCDMs. The AMCP Format is designed to encourage sharing of objective, credible, and relevant information on medical products.
May 2023 Legislative & Regulatory Briefing: AMCP’s Jennifer Mathieu Shares Tactics for Expanding Access to PDTs; ICYMI: Law CPE Sessions from AMCP 2023 Now Available on AMCP Learn; AMCP Submits Comments on Race and Ethnicity Statistical Standards; CMS Issues Final Medicare Part D DIR Reporting Guidance; Register Your Organization for the AMCP IRA Workshop Series.
On May 15, AMCP joined dozens of other health care organizations in a sign-on letter thanking the Biden Administration for relaunching the Cancer Moonshot program. First launched in 2016 with the mission to accelerate the rate of progress against cancer, the program's national goal is to reduce the death rate of cancer by at least 50% over the next 25 years. The letter applauds the program's prioritization of cancer prevention, especially though human papillomavirus (HPV) vaccination.